NASH Drug Testing | InSphero

Assess mechanisms of NASH induction and efficacy of NASH drugs

The 3D InSight™ Human Liver NASH Model ideal for the study of mechanisms of non-alcoholic steatohepatitis (NASH) induction and in vitro screening of NASH drug efficacy.  Because this advanced model includes all the critical liver cells and inducers needed to recapitulate the inflamed fatty liver disease state, it is a powerful model for NASH drug discovery and development. Our liver platform services team will work with you to design and implement a custom study package tailored to your research needs.

When you first partner with InSphero on a NASH discovery project, we recommend you start with a service evaluation project to rigorously test the model using up to four anti-NASH compounds.

3D InSight™NASH Discovery Evaluation Service

Study Design Details
Test compounds
  • 4 max.
  • healthy control
  • vehicle control
  • NASH condition
Positive Controls
  • Elafibranor for inflammation endpoint at Day 5
  • ALK5-inhibitor for fibrosis endpoint at Day 10
  • Day 5: Cytokine release by Luminex (TNF-α, IL-6, IL-8, MCP-1, MIP-α, IP-10)
  • Day 10: Albumin ELISA
  • Day 10: IHC for 7 markers: α-SMA, Col I, Col III, Col IV, Alb, CD68
  • Day 10: Collagen staining by Sirius Red (qualitative)

Find out how you can accelerate NASH drug

discovery with 3D InSight™ services.

Get Started

Related Services

In Vitro Toxicology

Microtissues and Kits

Liver Disease

Request Additional Resources

Human Liver in vitro NASH Model

Brochure: Human NASH Model

3D InSight Human Liver Fibrosis Model Brochure

Brochure: Fibrosis Model